King Andrew James 4
4 · CHINOOK THERAPEUTICS, INC. · Filed Aug 1, 2023
Insider Transaction Report
Form 4
King Andrew James
Head of Renal Discovery
Transactions
- Sale
Common Stock
2023-08-01$39.03/sh−1,168$45,586→ 19,157 total - Exercise/Conversion
Restricted Stock Units
2023-07-29−3,333→ 6,667 totalExp: 2025-07-29→ Common Stock (3,333 underlying) - Exercise/Conversion
Common Stock
2023-07-29+3,333→ 20,325 total
Footnotes (4)
- [F1]Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
- [F2]Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
- [F3]Each RSU represents a contingent right to receive one share of Issuer's common stock.
- [F4]The RSUs vest as to one-third (1/3) of the total award on the first, second, and third anniversaries of the grant date, subject to the reporting person's continued service to the Issuer on each vesting date.